851753-47-4

Basic information

• Product Name: 4-{2-fluoro-6-[(S)-3-methyl-1-((S_S)-2-methyl-propane-2-sulfinylamino)-butyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-{2-fluoro-6-[(S)-3-methyl-1-((S_S)-2-methyl-propane-2-sulfinylamino)-butyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 851753-47-4
• Molecular Weight: 469.664
• Mol File: 851753-47-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-{2-fluoro-6-[(S)-3-methyl-1-((S_S)-2-methyl-propane-2-sulfinylamino)-butyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{2-fluoro-6-[(S)-3-methyl-1-((S_S)-2-methyl-propane-2-sulfinylamino)-butyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester(851753-47-4)
• EPA Substance Registry System: 4-{2-fluoro-6-[(S)-3-methyl-1-((S_S)-2-methyl-propane-2-sulfinylamino)-butyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester(851753-47-4)

Safety Data

• Hazardous Substances Data: 851753-47-4(Hazardous Substances Data)

Upstream product

• 920-36-5 (2-methylpropyl)lithium 
• 851753-43-0 4-(2-fluoro-6-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 2646-91-5 2,3-difluorobenzaldehyde 
• 869478-18-2 4-{2-fluoro-6-[((S_S)-2-methyl-propane-2-sulfinylimino)-methyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 910300-34-4 4-{6-fluoro-2-[(1S)-((S)-tert-butanesulfinylamino)-3-methylbutyl]phenyl}-1-piperazine 

Relevant articles and documents

Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor

Benzylamine and pyridinemethylamine derivatives were synthesized and characterized as potent and selective antagonists of the melanocortin-4 receptor (MC4R). These compounds were also profiled in rodents for their pharmacokinetic properties. Two compounds with diversified profiles in chemical structure, pharmacological activities, and pharmacokinetics, 10 and 12b, showed efficacy in an established murine cachexia model. For example, 12b had a Ki value of 3.4 nM at MC4R, was more than 200-fold selective over MC3R, and had a good pharmacokinetic profile in mice, including high brain penetration. Moreover, 12b was able to stimulate food intake in the tumor-bearing mice and reverse their lean body mass loss. Our results provided further evidence that a potent and selective MC4R antagonist with appropriate pharmacokinetic properties might potentially be useful for the treatment of cancer cachexia.

LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO

Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): (I) including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, q, s, R1, R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, X1, X2, X3, X4 and Ar are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.